top of page

EMA: Plan for Digital Hub for the European Medicines Regulatory Network

Writer's picture: Sharan MuruganSharan Murugan

A technology capability investment plan has been published by the European Medicines Agency (EMA), which outlines how it plans to invest until 2025 to achieve its ambition of becoming the European medicines regulatory network's digital hub.


Technology Capability Investment Plan provides strategic guidance on how to achieve the digitalisation objectives of the European Medicines Regulatory Network and its stakeholders, addressing emerging information management needs as a result of new legislation and enabling the Network to become a data-driven, knowledge-based entity.

In order to help companies become more competitive, EU Digital Innovation Hubs will be one-stop shops that assist them in dynamically responding to digital challenges.


The main drivers of the Technology Capability Investment Plan (TCIP)

1. The need to accelerate digital business transformation and enable an agile operating model

2. Increasing business demand and new legislative requirements, requiring higher and faster throughput of the delivery pipeline

3. Aging technology landscape, bespoke and disparate databases and systems that become increasingly difficult and costly to maintain

4. The need to increase productivity through automation and data integration

5. New business opportunities coming from novel technologies and the need to support innovation


CLICK this LINK to know more about key operational and technology investments involved in the Technology Capability Investment Plan (TCIP).

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page